LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2021 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with severe genetic diseases of the central nervous system (CNS) and liver, including clinical programs in hemophilia B and Huntington’s disease and preclinical candidates in Fabry disease, spinocerebellar ataxia Type 3, temporal lobe epilepsy, Alzheimer’s, Parkinson’s, and ALS. www.uniQure.com
uniQure Contacts: | ||||
FOR INVESTORS: | FOR MEDIA: | |||
Maria E. Cantor | Chiara Russo | Tom Malone | ||
Direct: 339-970-7536 | Direct: 617-306-9137 | Direct: 339-970-7558 | ||
m.cantor@uniQure.com | c.russo@uniQure.com | t.malone@uniQure.com |
Ottawa, Ontario--(Newsfile Corp. - June 26, 2025) - As the Canadian Institute of Actuaries (CIA)…
PORTER WELCOMES A SEASONED LEADER TO ADVANCE MEMBER EXPERIENCE NATIONWIDE BALTIMORE, June 26, 2025 /PRNewswire/…
Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved…
SAN DIEGO, June 26, 2025 /PRNewswire/ -- Invetech, a global leader in solving complex manufacturing…
New research reveals that subtle response-time biomarkers—captured in minutes via digital assessments—can flag Alzheimer's and…
WarrantyTracker takes explant management to the next level -- expanding beyond warranty claims to support…